Annals of clinical and laboratory science · 2026
Commentary Note: Do We still Need Liquid Chromatography Combined with Mass Spectrometry for Therapeutic Drug Monitoring of Tacrolimus?
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kisler Tracy, Nelson Melody, Dasgupta Amitava
Аннотация
OBJECTIVE: In our laboratory, chemiluminescent microparticle immunoassay (CMIA) of tacrolimus on the Alinity i was implemented in February 2023 with an option for physicians to request liquid chromatography combined with mass spectrometry (LC-MS/MS) analysis to confirm the level of the immunoassay result.
METHODS: CMIA tacrolimus was performed on the Alinity i analyzer and the result was reported within 4h. However, if a physician requested LC-MS/MS analysis, the same whole blood specimen was sent to the reference laboratory, where the result was available within 24h. We then compared the LC-MS/MS value with the initial immunoassay result, which was performed in the same specimen.
RESULTS: From February 2, 2023, till November 18th, 2025, 51,833 tacrolimus tests were ordered in our laboratory. Out of all these specimens only 795 specimens (1.53%) were sent to the reference laboratory for further analysis by LC-MS/MS as requested by ordering physicians. In the majority of specimens (634 out of 795, 79.7%) difference between immunoassay and LC-MS/MS was less than 20%. However, 27 specimens (3.4%) showed positive bias over 30% with a highest bias of 76.7%.
CONCLUSION: LC-MS/MS is still needed for therapeutic drug monitoring of tacrolimus.
METHODS: CMIA tacrolimus was performed on the Alinity i analyzer and the result was reported within 4h. However, if a physician requested LC-MS/MS analysis, the same whole blood specimen was sent to the reference laboratory, where the result was available within 24h. We then compared the LC-MS/MS value with the initial immunoassay result, which was performed in the same specimen.
RESULTS: From February 2, 2023, till November 18th, 2025, 51,833 tacrolimus tests were ordered in our laboratory. Out of all these specimens only 795 specimens (1.53%) were sent to the reference laboratory for further analysis by LC-MS/MS as requested by ordering physicians. In the majority of specimens (634 out of 795, 79.7%) difference between immunoassay and LC-MS/MS was less than 20%. However, 27 specimens (3.4%) showed positive bias over 30% with a highest bias of 76.7%.
CONCLUSION: LC-MS/MS is still needed for therapeutic drug monitoring of tacrolimus.